HK1205457A1 - N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridin yl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer - Google Patents
N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridin yl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer Download PDFInfo
- Publication number
- HK1205457A1 HK1205457A1 HK15106028.6A HK15106028A HK1205457A1 HK 1205457 A1 HK1205457 A1 HK 1205457A1 HK 15106028 A HK15106028 A HK 15106028A HK 1205457 A1 HK1205457 A1 HK 1205457A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cancer
- amg
- cells
- tumor
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24152709P | 2009-09-11 | 2009-09-11 | |
| US241527P | 2009-09-11 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK13100715.9A Addition HK1173655B (en) | 2009-09-11 | 2010-09-09 | N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK13100715.9A Division HK1173655B (en) | 2009-09-11 | 2010-09-09 | N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1205457A1 true HK1205457A1 (en) | 2015-12-18 |
Family
ID=43216900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15106028.6A HK1205457A1 (en) | 2009-09-11 | 2013-01-16 | N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridin yl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US20120028917A1 (https=) |
| EP (2) | EP2818170B1 (https=) |
| JP (1) | JP5851403B2 (https=) |
| KR (1) | KR20120082896A (https=) |
| CN (1) | CN102869361A (https=) |
| AU (1) | AU2010292225C1 (https=) |
| BR (1) | BR112012008325A2 (https=) |
| CA (1) | CA2773838C (https=) |
| CL (1) | CL2012000640A1 (https=) |
| CR (1) | CR20120171A (https=) |
| DK (1) | DK2475368T3 (https=) |
| EA (1) | EA020526B1 (https=) |
| ES (1) | ES2528485T3 (https=) |
| HK (1) | HK1205457A1 (https=) |
| HR (1) | HRP20150104T1 (https=) |
| HU (1) | HUE024568T2 (https=) |
| IL (1) | IL218569A0 (https=) |
| MA (1) | MA33658B1 (https=) |
| ME (1) | ME02048B (https=) |
| MX (1) | MX2012003041A (https=) |
| NZ (1) | NZ598758A (https=) |
| PE (1) | PE20120895A1 (https=) |
| PH (1) | PH12012500504A1 (https=) |
| PL (1) | PL2475368T3 (https=) |
| PT (1) | PT2475368E (https=) |
| RS (1) | RS53807B1 (https=) |
| SG (1) | SG179102A1 (https=) |
| SI (1) | SI2475368T1 (https=) |
| SM (1) | SMT201500028B (https=) |
| TN (1) | TN2012000110A1 (https=) |
| TW (1) | TW201121956A (https=) |
| UA (1) | UA107675C2 (https=) |
| WO (1) | WO2011031842A1 (https=) |
| ZA (1) | ZA201202472B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8921367B2 (en) | 2012-05-31 | 2014-12-30 | Amgen Inc. | Use of AMG 900 for the treatment of cancer |
| CN103664737A (zh) * | 2012-09-25 | 2014-03-26 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
| KR101701235B1 (ko) | 2013-09-30 | 2017-02-03 | 한국원자력의학원 | Ｈｒｐ-3 억제제를 포함하는 방사선 또는 약물내성 암의 치료용 약학 조성물 |
| BR112016010564A2 (pt) | 2013-11-11 | 2017-10-10 | Amgen Inc | terapia de combinação incluindo um inibidor de mdm2 e um ou mais agentes farmaceuticamente ativos para tratamento de cânceres |
| WO2015084649A1 (en) | 2013-12-03 | 2015-06-11 | Amgen Inc. | Crystalline forms of n-(4-((3-(2-amino-4-pyrimidinyl) - 2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1 -phthalazinamine pharmaceutically acceptable salts and uses thereof |
| RU2713179C2 (ru) * | 2014-02-21 | 2020-02-04 | Фрост Биолоджик, Инк. | Антимитотические амиды для лечения рака и пролиферативных заболеваний |
| EP3443351A4 (en) * | 2016-04-15 | 2019-12-18 | Felicitex Therapeutics, Inc. | COMBINATIONS FOR THE TREATMENT OF NEOPLASIA BY TARGETING RESTING CELLS AND INHIBITORS OF MITOSIS |
| AU2018273356B2 (en) | 2017-05-22 | 2021-09-16 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| AU2018329920B2 (en) | 2017-09-08 | 2022-12-01 | Amgen Inc. | Inhibitors of KRAS G12C and methods of using the same |
| CA3098574A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| MX2020012204A (es) | 2018-06-11 | 2021-03-31 | Amgen Inc | Inhibidores de kras g12c para tratar el cáncer. |
| US11285156B2 (en) | 2018-06-12 | 2022-03-29 | Amgen Inc. | Substituted piperazines as KRAS G12C inhibitors |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| WO2020236947A1 (en) | 2019-05-21 | 2020-11-26 | Amgen Inc. | Solid state forms |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060178318A1 (en) * | 2003-07-03 | 2006-08-10 | Shubha Anand | Use of aurora kinase inhibitors for reducing the resistance of cancer cells |
| CN101405282B (zh) * | 2006-01-23 | 2015-03-25 | 安姆根有限公司 | 极光激酶调节剂和使用方法 |
| DK1984353T3 (en) * | 2006-01-23 | 2016-03-14 | Amgen Inc | Aurorakinasemodulatorer and method of use |
| US7560551B2 (en) * | 2006-01-23 | 2009-07-14 | Amgen Inc. | Aurora kinase modulators and method of use |
| GB0609619D0 (en) * | 2006-05-16 | 2006-06-21 | Astrazeneca Ab | Combination |
| GB0609621D0 (en) * | 2006-05-16 | 2006-06-21 | Astrazeneca Ab | Novel co-crystal |
-
2010
- 2010-09-09 NZ NZ598758A patent/NZ598758A/en not_active IP Right Cessation
- 2010-09-09 PE PE2012000323A patent/PE20120895A1/es not_active Application Discontinuation
- 2010-09-09 PL PL10755044T patent/PL2475368T3/pl unknown
- 2010-09-09 CN CN2010800512813A patent/CN102869361A/zh active Pending
- 2010-09-09 HR HRP20150104AT patent/HRP20150104T1/hr unknown
- 2010-09-09 WO PCT/US2010/048247 patent/WO2011031842A1/en not_active Ceased
- 2010-09-09 UA UAA201204585A patent/UA107675C2/ru unknown
- 2010-09-09 ES ES10755044.4T patent/ES2528485T3/es active Active
- 2010-09-09 HU HUE10755044A patent/HUE024568T2/hu unknown
- 2010-09-09 MX MX2012003041A patent/MX2012003041A/es active IP Right Grant
- 2010-09-09 ME MEP-2015-10A patent/ME02048B/me unknown
- 2010-09-09 EA EA201270383A patent/EA020526B1/ru not_active IP Right Cessation
- 2010-09-09 PH PH1/2012/500504A patent/PH12012500504A1/en unknown
- 2010-09-09 US US12/878,539 patent/US20120028917A1/en not_active Abandoned
- 2010-09-09 CA CA2773838A patent/CA2773838C/en active Active
- 2010-09-09 JP JP2012528891A patent/JP5851403B2/ja active Active
- 2010-09-09 EP EP14186203.7A patent/EP2818170B1/en active Active
- 2010-09-09 BR BR112012008325A patent/BR112012008325A2/pt not_active IP Right Cessation
- 2010-09-09 PT PT107550444T patent/PT2475368E/pt unknown
- 2010-09-09 KR KR1020127009226A patent/KR20120082896A/ko not_active Ceased
- 2010-09-09 AU AU2010292225A patent/AU2010292225C1/en active Active
- 2010-09-09 RS RS20150065A patent/RS53807B1/sr unknown
- 2010-09-09 DK DK10755044T patent/DK2475368T3/en active
- 2010-09-09 EP EP10755044.4A patent/EP2475368B1/en active Active
- 2010-09-09 SG SG2012017422A patent/SG179102A1/en unknown
- 2010-09-09 SI SI201030865T patent/SI2475368T1/sl unknown
- 2010-09-10 TW TW099130742A patent/TW201121956A/zh unknown
-
2012
- 2012-03-11 IL IL218569A patent/IL218569A0/en unknown
- 2012-03-12 TN TNP2012000110A patent/TN2012000110A1/en unknown
- 2012-03-12 CL CL2012000640A patent/CL2012000640A1/es unknown
- 2012-04-04 ZA ZA2012/02472A patent/ZA201202472B/en unknown
- 2012-04-04 MA MA34753A patent/MA33658B1/fr unknown
- 2012-04-10 CR CR20120171A patent/CR20120171A/es unknown
-
2013
- 2013-01-16 HK HK15106028.6A patent/HK1205457A1/en unknown
-
2015
- 2015-02-09 SM SM201500028T patent/SMT201500028B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2475368B1 (en) | N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridin yl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer | |
| JP6754071B2 (ja) | メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用 | |
| JP6433085B2 (ja) | がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン | |
| KR20170017932A (ko) | Ｍｄｍ２ 억제제의 간헐적 투여 | |
| TW201609094A (zh) | 治療癌症之新穎方法 | |
| US20220241294A1 (en) | Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer | |
| HK1173655B (en) | N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer | |
| US20190133998A1 (en) | Treatment of tumors with inhibitors of cxcl12 signaling and subtherapeutic amounts of chemotherapeutic agents | |
| EP3070092B1 (en) | 3-phenyl-thiazolo[3,2-a]benzimidazole derivatives as aldehyde dehydrogenase 1 (aldh-1) modulators for the treatment of breast cancer or leukemia, and for manipulating cultured aldh-1 positive breast cancer or leukemia cells | |
| CN112999236B (zh) | 乌本苷用于治疗脑干胶质瘤的用途 | |
| WO2010085462A1 (en) | Method for treating triple negative breast cancer |